Idiopathic Pulmonary Fibrosis (IPF) is a serious lung disease with unknown cause, characterized by scarring of the lungs. This study tests a new drug, BMS-986278, for its effectiveness, safety, and how well patients tolerate it. High-resolution computed tomography (HRCT) is a special imaging test used to confirm the diagnosis of IPF.

To join the study, participants should be 40 years or older and have been diagnosed with IPF within the last 7 years. If already on medications pirfenidone or nintedanib for IPF, they must have been stable on these for at least 3 months. If not on these medications, they shouldn't have taken them in the past month. Women must use effective birth control and have a negative pregnancy test. Men must agree to use barrier contraception like condoms.

People who had a stroke recently, have heart failure symptoms, or have had cancer recently cannot join. Other specific rules apply.

• Length: Details about the study length are not provided.
• Visits: Frequency of visits is not specified.
• Compensation: Not mentioned, consider asking the study team.